Taking T2DM to Heart: Treating to Decrease CVD—Part 1
Slide Lecture Series
Time to Complete
May 31, 2019
May 31, 2020
0.75 / AMA PRA Category 1 CreditTM
This activity is provided by Forefront Collaborative.
This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC.
Patients with type 2 diabetes mellitus (T2DM) face increased risk for coronary heart disease and other vascular disorders, including heart failure, cardiac dysrhythmia, sudden death, hypertensive disease, pulmonary embolism, and aortic aneurysm. In Part 1 of this education, Dr. Richard Pratley will present A New Look at Current Clinical Guidelines, CVOT, and Evidence-based Treatment Options and discuss current data and equip learners with strategies to address patient barriers and to apply emerging and adjunctive therapies to daily clinical practice. This activity will focus on key clinical guideline updates and their application for individualizing care plans and minimizing negative cardiovascular outcomes in T2DM. Learners will also be provided with a summary of safety/efficacy data of new and emerging therapies to reduce the risk of cardiovascular disease (CVD), renal comorbidities, and CVD death.
The target audience for this activity includes members of the diabetes care team (eg, primary care physicians, nurse practitioners, physician assistants, internal medicine physicians, endocrinologists, cardiologists, and diabetes educators). Other healthcare professionals who treat or manage patients with diabetes may also benefit from participation.
Upon completion of the activity, participants should be able to:
Summarize evidence-based practice guidelines for glycemic control in patients with T2DM.
Describe the efficacy/safety profiles of available antihyperglycemic agents and their impact on cardiovascular and renal issues in patients with T2DM.
Outline clinical trial data of specific sodium-glucose cotransporter 2 (SGLT-2) inhibitors, glucagon-like peptide 1 receptor agonists (GLP-1 RAs), and dipeptidyl peptidase-4 inhibitors (DPP-4is) in patients with T2DM as demonstrated in cardiovascular outcomes trials (CVOTs).
There is no fee for this educational activity.
Conflict Of Interest Disclosure Policy
Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s)*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below.
*The ACCME defines a commercial interest as any entity producing, marketing, reselling, or distributing healthcare goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests—unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.
Richard Pratley, MD AdventHealth Samuel E. Crockett Chair in Diabetes Research, Medical Director, AdventHealth Diabetes Institute Senior Investigator and Diabetes Program Lead, Translational Research Institute for Metabolism and Diabetes Orlando, Florida
Dr. Pratley discloses the following: Consultant: AstraZeneca, GlaxoSmithKline, Glytec, Janssen, Ligand, Lilly, Merck, Mundipharma, Novo, Pfizer, and Sanofi; Speaker’s Bureau: Novo Grant Funding: Janssen, Lexicon, Ligand, Lilly, Merck, Novo, and Sanofi
Accredited Provider Disclosure
Forefront Collaborative Sydney Pate has nothing to disclose in regards to financial relationship(s) with commercial interest. Maria Rovere has nothing to disclose in regards to financial relationship(s) with commercial interest.
AMA PRA Category 1 Credit(s)TM
Forefront Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Forefront Collaborative designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 CreditTM . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Unlabeled Use
This continuing medical education activity may include reference(s) to unlabeled or unapproved uses of drugs.
The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative or Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC.
To obtain credit, a score of 80% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/Exam History, which you can access at any time.